Outpatient Oncology Aromatherapy for Symptom Management

Anxiety Clinical Trial

Official title:

Outpatient Oncology Aromatherapy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04449315
• Other study ID #: CentralDuPage
• Status: Not yet recruiting
• Phase: N/A
• Start date: August 2020
• Est. completion date: June 2021

Study information

• Verified date: June 2020
• Source: Central DuPage Hospital
• Contact: Lorraine Mack, MSN
• Phone: 630-315-6025
• Email: lorraine.mack[@]nm.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to determine whether using aromatherapy during chemotherapy infusion treatments in the outpatient Oncology setting promote relief of nausea and anxiety.

The objectives of this study are: 1. To promote relief of nausea using peppermint aromatherapy oil in an outpatient oncology setting. 2. To promote relief of anxiety using lavender aromatherapy oil in an outpatient oncology setting.

Description:

Subject Selection: Every outpatient oncology patient experiencing nausea and/or anxiety during an infusion visit will be offered hospital-approved aromatherapy of Peppermint oil or Lavender oil. If patient says yes, then they will be selected for the study and infusion nurse will notify the study co-investigators or principal investigator. Informed consent will then be obtained by co-investigators or principal investigator of the study. The consents as well as the data collection tool sheets will be numbered without identifying patient's personal information. Peppermint oil aromatherapy and/or lavender oil aromatherapy will then be administered to consented patients.

Method of Subject Identification and Recruitment: Every outpatient oncology patient experiencing nausea and/or anxiety during an infusion visit will be offered hospital- approved aromatherapy of Peppermint oil or Lavender oil. If patient says yes, then they will be selected for the study and infusion nurse will notify the study co-investigators or principal investigator. Informed consent will then be obtained by co-investigators or principal investigator of the study. The consents as well as the data collection tool sheets will be numbered without identifying patient's personal information. Peppermint oil aromatherapy and/or lavender oil aromatherapy will then be administered to consented patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: June 2021
• Est. primary completion date: May 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

All outpatient Oncology patients > 18 years of age Non pregnant Not cognitively impaired English speaking only Patients who report nausea and/or anxiety

Exclusion Criteria:

All outpatient oncology patients <18 years of age Pregnant Cognitively impaired Non-English Speaking Patients who do not report nausea and/or anxiety Patients with a known allergy to peppermint and/or lavender aromatherapy oil

Related Conditions & MeSH terms

• Anxiety
• Nausea

Intervention

Other:
• Young Living Lavender Essential Oil
For qualified patients one to two drops of hospital approved essential oil will be placed on a 4X4 gauze and will be offered to the patient during their infusion visit. This gauze will be placed in a sealable clear plastic bag and the patient will be instructed to use one sniff at a time.

Locations

Country	Name	City	State
United States	Central DuPage	Winfield	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Central DuPage Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Post Intervention Interview From	After the patients' infusion they will be asked questions from this form	Immediately upon Completion of the patient's infusion